Study on an Injectable Chitosan–Lignin/Poloxamer Hydrogel Loaded with Platelet-Rich Plasma for Intrauterine Adhesion Treatment
Polymers · 11.02.2025 · 17 (4) · 474
DOI: 10.3390/polym17040474 ↗Kurz gefasst
Fachartikel in der Zeitschrift Polymers, online erschienen am 11.02.2025. Verfasst von Zhipeng Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory Developmental Biology of Freshwater Fish, School Life Science, Hunan Normal University, Changsha 410081, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control, nnovation and entrepreneurship fund for college students of Hunan Normal University, innovation and entrepreneurship fund for college students of Hunan Normal University.
Abstract (Originalsprache)
It is a great challenge to obtain an ideal hydrogel for the clinical treatment of intrauterine adhesion (IUA) disease. Here, a novel injectable chitosan–lignin/poloxamer hydrogel loaded with platelet-rich plasma (CL-PF127@PRP) was prepared by self-assembly at room temperature. Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), rheological analysis, and injectable writing were used to characterize the structure of the hydrogel. The results confirmed that the amino group of chitosan and the sulfonic group of sodium lignosulfonate were ionic-crosslinked by electrostatic attraction, which stabilized the three-dimensional structure of the PF127 hydrogel loaded with PRP, and PRP made the porous structure gradually become tight. Moreover, the CL-PF127@PRP hydrogel displayed good injectability and a solid state. The soaking experiment showed that the CL-PF127@PRP hydrogel had suitable degradation at pH = 7 and a good PRP release rate (PRP release 70% at 96 h). Cell experiments in vitro demonstrated that the CL-PF127@PRP hydrogel possessed good biocompatibility, an anti-inflammatory function, and pro-angiogenic activity. Furthermore, an animal experiment of skin wound and IUA confirmed that the skin wound closure rate of the CL-PF127@PRP hydrogel was over 50% on the seventh day. PRP improved the thickness of the endometrium and uterus receptivity, suggesting that the CL-PF127@PRP hydrogel offers great promise for the clinical treatment of IUA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory Developmental Biology of Freshwater Fish, School Life Science, Hunan Normal University, Changsha 410081, China.
- National & Local Joint Engineering Laboratory for New Petro-chemical Materials and Fine Utilization of Resources, College of Chemistry and Chemical Engineering, Hunan Normal University, Changsha 410081, China.
ORCID-Profile: Xiang Hu, Liuyun Jiang
Förderung
- Hunan Provincial Key Laboratory of Regional Hereditary Birth Defects Prevention and Control
- nnovation and entrepreneurship fund for college students of Hunan Normal University
- innovation and entrepreneurship fund for college students of Hunan Normal University
Zitieren
APA
Yu, Z., Min, Y., Ouyang, Q., Fu, Y., Mao, Y., Xiang, S., Hu, X., & Jiang, L. (2025). Study on an Injectable Chitosan–Lignin/Poloxamer Hydrogel Loaded with Platelet-Rich Plasma for Intrauterine Adhesion Treatment. Polymers, 17(4), 474. https://doi.org/10.3390/polym17040474
Vancouver
Yu Z, Min Y, Ouyang Q, Fu Y, Mao Y, Xiang S, et al. Study on an Injectable Chitosan–Lignin/Poloxamer Hydrogel Loaded with Platelet-Rich Plasma for Intrauterine Adhesion Treatment. Polymers. 2025;17(4):474. doi:10.3390/polym17040474
BibTeX
@article{Yu2025,
author = {Yu, Zhipeng and Min, Yang and Ouyang, Qi and Fu, Yuting and Mao, Ying and Xiang, Shuanglin and Hu, Xiang and Jiang, Liuyun},
title = {Study on an Injectable Chitosan–Lignin/Poloxamer Hydrogel Loaded with Platelet-Rich Plasma for Intrauterine Adhesion Treatment},
journal = {Polymers},
year = {2025},
volume = {17},
number = {4},
pages = {474},
doi = {10.3390/polym17040474}
}
EUVIMED